Regeneron Pharma Q4 Results Top Estimates - Update

RTTNews | Před 471 dny
Stocktwits
Regeneron Pharma Q4 Results Top Estimates - Update

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Značky : REGN
Stocktwits
read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | Před 290 dny
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | Před 324 dny
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | Před 1052 dny
Malaysia Stock Market Tipped To Open To The Upside

Malaysia Stock Market Tipped To Open To The Upside

The Malaysia stock market has ticked lower in back-to-back sessions, shedding almost a dozen points or 0.8 percent along the way. The Kuala Lumpur Composite Index now sits just above the 1,570-point plateau although it may find support on Monday.
RTTNews | Před 19 minutami
Japan Stock Market May Find Support On Monday

Japan Stock Market May Find Support On Monday

The Japanese stock market has moved lower in three straight sessions, dropping almost 450 points or 1.3 percent along the way. The Nikkei 225 now sits just above the 37,750-point plateau although it may find traction on Monday.
RTTNews | Před 34 minutami
Additional Support Expected For South Korea Shares

Additional Support Expected For South Korea Shares

The South Korea stock market bounced higher again on Friday, one day after ending the three-day winning streak in which it had advanced more than 60 points or 2.4 percent. The KOSPI now sits just above the 2,625-point plateau and it may add to its winnings on Monday.
RTTNews | Před 49 minutami
China Data On Tap For Monday

China Data On Tap For Monday

China is scheduled to release a batch of data on Monday, headlining a busy day for Asia-Pacific economic activity. On Tap are April figures for industrial production, retail sales, fixed asset investment, house prices and unemployment.
RTTNews | Před 1 h 49 min
Nástroje
Ekonomický kalendář
Market Hours
Interest Rates
Holidays Calendar
Forexový trh
Forex volatilita
Korelace Forexu
Novinky na Forexu
forex analysis
COT údaje
Likvidita
Forex kalkulačky
Forex Tepelná mapa
Indicators Heatmap
Komunita
Komunita
Systémy
Nejpopulárnější systémy
Strategie
Soutěže
Forexové grafy
Forexový sentiment
Indikátor Outlook
Recenze
Brokeři
Prop Trading Firms
Služby VPS
Poskytovatelé signálu
Služby programování EA
Affiliate Programs
Služby PAMM Brokera
Služby slevového programu
Obchodní platformy
Odborní poradci
Kryptoburzy
Trading Courses
Brokeři
Forex Spready
Nabídky Forex brokerů
Swapy Forex brokerů
Objem brokera Forexu
Propagační akce Forex Brokera Press Release
Platforma
Miniaplikace
Funkce
API
RSS
Stock Portfolio
Affiliate Software
Rozšířené grafy
Podpora
Faq
Pomoc
Kontaktuj nás
Nahlásit chybu!
O
Blog
& copy; 2025 Myfxbook Ltd. Všechna práva vyhrazena.
UPOZORNĚNÍ NA VYSOKÉ RIZIKO: Obchodování s devizami přináší vysokou úroveň rizika, které nemusí být vhodné pro všechny investory. Páka vytváří další rizika a ztráty. Než se rozhodnete obchodovat s devizami, důkladně zvažte své investiční cíle, úroveň zkušeností a toleranci vůči riziku. Můžete přijít o část nebo všechny své počáteční investice. Neinvestujte peníze, které si nemůžete dovolit ztratit. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Všechny údaje a informace jsou poskytovány "tak, jak jsou". pouze pro informační účely a nejsou určeny pro obchodní účely nebo rady. Výkonnost v minulosti neznamená výkonnost v budoucnosti.